HPN Symposium

Swipe left or right to browse abstracts

Poster · Neuromuscular Disorders

Riliprubart in CIDP: Time and Magnitude of Response Analysis from a Phase-2 Trial

0 votes
9 views

R. A. Lewis, MD1, J. Lin, MD2, A. Dionne, MD, FRCPC3, Y. Lu, PhD4, M. Alonso-Alonso, MD, PhD5, A. Paker, MD, MPH5, L. Querol, MD, PhD6

  1. 1 Department of Neurology, Cedars Sinai Medical Center, Los Angeles, CA, USA
  2. 2 Department of Neurology and Rare Disease Center, Huashan Hospital, Fudan University, Shanghai, People’s Republic of China
  3. 3 CHU de Quebec Universite Laval, Quebec, Canada
  4. 4 Sanofi R&D, Evidence Generation and Decision Science, Cambridge, MA, USA
  5. 5 Sanofi, Cambridge, MA, USA
  6. 6 Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Centro para la Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Madrid, Spain.

Introduction: Riliprubart, a first-in-class humanized IgG4-monoclonal antibody, selectively inhibits activated-C1s in classical complement pathway and can be self-administered subcutaneously via auto-injector. In Phase-2 trial (NCT04658472), riliprubart demonstrated favorable safety and encouraging efficacy in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

Objective: To present time and magnitude of response analyses to characterize clinical benefits of riliprubart.

Conclusion: Author Disclosures RA. Lewis: Consultant with CSL Behring, Grifols, Pfizer, Sanofi (Steering Committee), argenx, Pharnext, Roche, Johnson & Johnson, Takeda, Boehringer Ingelheim (DSMB), and Momenta. He is also part of the scientific advisory boards Alnylam and Akcea and medical advisory board The GBS-CIDP Foundation International. J. Lin: Nothing to disclose. A. Dionne: Received honoraria from argenx and Alexion for conference and ad board. Y. Lu, M. Alonso-Alonso, A. Paker: Employees of Sanofi and may hold shares and/or stock options in the company. L. Querol: Received research grants from Instituto de Salud Carlos III – Ministry of Economy and Innovation (Spain), CIBERER, Fundació La Marató, GBS-CIDP Foundation International, UCB and Grifols. He received speaker or expert testimony honoraria from CSL Behring, Novartis, Sanofi, Merck, Annexon, Alnylam, Biogen, Janssen, Lundbeck, argenx, UCB, Dianthus, LFB, Avilar Therapeutics, Octapharma and Roche. He serves at Clinical Trial Steering Committee for Sanofi and was Principal Investigator for UCB’s CIDP01 trial.